

**Remarks**

Claims 1-12 have been cancelled. Claim 15 has been amended in response to the Office Action. Applicants assert that the amendment raises no issue of new matter. Basis for the amendment may be found in the specification at: page 151, line 1. Entry of the amendments and allowance of the claims in view of the amendments and the following discussion are respectfully requested.

Applicants gratefully acknowledge allowance of claims 13 and 14 in the Office Action. Claim 15 was rejected under 35 U.S.C. § 112, second paragraph, as allegedly vague and indefinite in view of the term “formulation”. Applicants have replaced “formulation” with “composition”. Pharmaceutical compositions are clearly discussed on page 151 of the specification as originally filed. Applicants respectfully submit that claim 15 is now in condition for allowance. Allowance of the claims is respectfully requested.

Respectfully submitted,

/Robert D. Titus/

Robert D. Titus  
Attorney for Applicants  
Registration No. 40,206  
Phone: 317-277-3729

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

November 20, 2007

---